**UNITED
      STATES**


**SECURITIES
      AND EXCHANGE COMMISSION**


**Washington,
      D.C. 20549**







**FORM
      10-KSB**




x
      ANNUAL REPORT UNDER
      SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934




For
      the fiscal year ended December 31,
      2006




o
      TRANSITION REPORT UNDER
      SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934









Commission
      file number: 333-46828




Karver
                International, Inc.
              (Name
                of small business issuer in its charter)New
                York
              (State
                or other jurisdiction of
              incorporation
                or organization)
            13-3526402
              (I.R.S.
                Employer Identification No.)601
                Brickell Key Drive, Suite 901,
              Miami,
                FL
              (Address
                of principal executive offices)
            33131
              (Zip
                Code)




Registrant’s
      telephone number, including area code: (305)
      350-3996




Securities
      registered under Section 12(b) of the Exchange Act: None


Securities
      registered under Section 12(g) of the Exchange Act: None




Check
      whether the issuer (1) filed
      all reports required to be filed by Section 13 or 15(d) of the Exchange Act
      during the past 12 months (or for such shorter period that the registrant was
      required to file such reports), and (2) has been
      subject to such filing requirements for the past 90 days. Yes x No o




Check
      if
      there is no disclosure of delinquent filers in response to Item 405 of
      Regulation S-B contained in this form, and no disclosure will be contained,
      to
      the best of registrant’s knowledge, in definitive proxy or information
      statements incorporated by reference in Part III of this Form 10-KSB or any
      amendment to this Form 10-KSB. x




Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12b-2 of the Exchange Act).


Yes o No x




The
      issuer had $0.00 in revenues for the year ended December 31, 2006.




As
      of
      March 26, 2007, the aggregate market value of the voting stock held by
      non-affiliates of the registrant was approximately $8,866,950. Such aggregate
      market value was computed by reference to the closing price of the Common Stock
      as reported on the Over-The-Counter Bulletin Board on March 26,
      2007.




As
      of
      March 26, 2007, 13,641,461 shares of the registrant’s Common Stock, par value
      $0.0001 per share were issued and outstanding.




**Documents
      Incorporated By Reference** :
      None




Transitional
      Small Business Disclosure Format. Yes o No x







**Table
      of Contents**





Cautionary
      Note Regarding Forward-Looking Statements


PART
                  I.Item
                  1.
              
              Description
                  of Business
              
              2Item
                  2.
              
              Description
                  of Property
              
              7Item
                  3.
              
              Legal
                  Proceedings
              
              7Item
                  4.
              
              Submission
                  of Matters to a Vote of Security Holders
              
              7PART
                  II.Item
                  5.
              
              Market
                  for Common Equity and Related Stockholder Matters
              
              8Item
                  6.
              
              Management’s
                  Discussion and Analysis or Plan of Operation
              
              9Item
                  7.
              
              Financial
                  Statements
              
              12Item
                  8.
              
              Changes
                  in and Disagreements with Accountants on Accounting and Financial
                  Disclosure
              
              22Item
                  8A.
              
              Controls
                  and Procedures
              
              22Item
                  8B.
              
              Other
                  Information
              
              22PART
                  III.Item9.
              
              Directors,
                  Executive Officers, Promoters, Control Persons and Corporate Governance;
                  Compliance with Section 16(a) of the Exchange Act
              
              23Item10.
              
              Executive
                  Compensation
              
              24Item11.
              
              Security
                  Ownership of Certain Beneficial Owners and Management and Related
                  Stockholder Matters
              
              25Item12.
              
              Certain
                  Relationships and Related Transactions, and Director
                  Independence
              
              25Item
                  13.
              
              Exhibits
              
              26Item14.
              
              Principal
                  Accountant Fees and Services
              
              27










**Cautionary
      Note Regarding Forward-Looking Statements**




Statements
      included in this Annual Report on Form 10-KSB that are not historical facts
      are
“forward-looking statements” within the meaning of the Private Securities
      Litigation Reform Act of 1995. Such statements are based on current
      expectations, but involve risks and uncertainties that could cause actual
      results to differ from those projected. The use of terminology such as “expect,”
“believe,” “intend,” “continue,” “anticipate” and other similar expressions
      generally identify “forward-looking statements.” They include statements
      relating to, among other things, future capital, business strategies, expansion
      and growth of operations, cash flow, marketing of products and services, and
      development of new products and services. Factors that could cause actual
      results to differ materially include, but are not limited to, those described
      throughout this report, in particular those in the section of Item 1 entitled
      “Risk Factors.” The Company disclaims any obligation to update or revise any
      forward-looking statements to reflect events or circumstances occurring
      hereafter.





**PART
      I**




**ITEM
      1. **DESCRIPTION
      OF**** **BUSINESS**




Karver
      International, Inc. (f/k/a Medeorex, Inc.), a New York corporation (“Karver”,
“we”, “us”, “our”, or the “Company”) and its wholly owned subsidiary, MDRX, Inc.
      (“MDRX”), a Delaware corporation, is an emerging health and pharmaceutical
      services company. We are actively pursuing corporate and product acquisitions
      in
      order to establish a competitive position in these industries.




We
      were
      originally incorporated under the name Phyllis Maxwell’s Groups, Inc. in New
      York on April 18, 1989. On August 3, 2001, we filed a Certificate of Amendment
      changing our name to Clixtix, Inc. Then, on August 31, 2001, we and our
      subsidiary entered into an Agreement and Plan of Reorganization through which
      we
      sold to our subsidiary all of our tangible and intangible assets appearing
      on
      our balance sheet as of June 30, 2001. Our subsidiary also assumed all of our
      liabilities. As consideration for this agreement, we received 100 shares of
      our
      subsidiary’s common stock, which represented all of the issued and outstanding
      stock of our subsidiary. Through our subsidiary, we provided services for groups
      interested in attending New York’s Broadway and Off-Broadway theater
      productions.




During
      2001, we conducted an initial public offering in which we offered and sold
      1,000,000 shares of our common stock for net proceeds of $50,000. Such proceeds
      were utilized for corporate development and working capital.




On
      September 13, 2004, Ms. Phyllis Maxwell, our former president and controlling
      shareholder, sold 5,086,600 shares of our common stock, representing
      approximately 49% of the Company’s then issued and outstanding shares, to First
      Jemini Family Trust (the “Trust”), a Canadian discretionary family trust which
      was not affiliated with Ms. Maxwell. The Trust is a discretionary family trust
      for the benefit of our Chairman and President, his spouse and family members.
      Such beneficiaries possess no right to the Trust and therefore have no direct
      beneficial ownership of shares held by the Trustee.




Also,
      on
      September 13, 2004, pursuant to a Share Exchange Agreement with MDRX, a
      privately held Delaware corporation with intentions of operating in the health
      services industry, we issued to the stockholders of MDRX an aggregate of
      4,490,226 shares of our common stock, representing approximately 31% of our
      issued and outstanding shares after the issuance, in exchange for all of the
      issued and outstanding shares of MDRX. One of the former controlling
      shareholders of MDRX is our Chairman and President’s spouse. Although she is
      also a beneficiary of the First Jemini Trust, as noted above, she does not
      possess any right to vote or dispose of the assets of that trust. As a
      consequence, the transaction with MDRX was treated for accounting purposes
      as a
      purchase and not a reverse merger. Pursuant to this Share Exchange Agreement,
      MDRX became our wholly owned subsidiary.




2




Immediately
      following the closing under the Share Exchange Agreement, we discontinued our
      theater ticket business by selling that operation and its assets to Aisle Seats,
      Inc. (“Aisle Seats”), a company controlled by our former president and majority
      stockholder. As consideration, Aisle Seats assumed all of the liabilities of
      the
      theater ticket business operation. To reflect the change in business operations,
      on September 23, 2004, the Company changed its name from “Clixtix, Inc.” to
“Medeorex, Inc.”. The Company subsequently changed its name from Medeorex to
“Karver International, Inc.” (“Karver”) on November 3, 2005.




The
      Company is considered to be in the development stage as defined by Statement
      of
      Financial Accounting Standards No. 7, *Accounting
      and Reporting by Development Stage Enterprises.*




On
      May 6,
      2005, we agreed to acquire a minority interest in CardioGenics, Inc.
      (“CardioGenics”), a privately held Canadian biotechnology and medical devices
      company, subject to successful completion of the due diligence process.
      CardioGenics is focused on the development of superior products for the
      In-Vitro-Diagnostics cardiac testing market and several other related
      proprietary technologies related to the screening and testing of cardiac
      ailments. The terms of this potential investment were subsequently modified
      by
      both parties on June 14, 2005, on February 24, 2006, and again on February
      2007
      respectively furthermore on March 1, 2007 the parties agreed to extend the
      closing date to June 30, 2007. During
      such periods the Company has been assisting CardioGenics in management,
      marketing and development of its business model and
      technologies.




Based
      on
      current terms, and subject to the satisfactory completion of due diligence
      and
      pursuant to a number of conditions being met by CardioGenics, the Company has
      agreed to potentially invest $2.5 million in the form of a private placement
      in
      voting convertible preferred stock of CardioGenics pursuant to which the Company
      will own approximately 20% of CardioGenics by the end of June 2007.
      Additionally, in return for the Karver investment and in order for Karver to
      obtain a majority control of CardioGenics as the Company may require,
      CardioGenics agreed to grant Karver a two-year warrant to purchase sufficient
      additional shares at a pre-set valuation to acquire a majority control of
      CardioGenics. In addition to the successful completion of its due diligence
      on
      CardioGenics, in order to complete the investment, Karver will be required
      to
      raise capital for the contemplated transaction through a combination of
      additional borrowings and the issuance of debt and equity securities. At this
      time, no such financing transactions have been agreed to or finalized.




In
      addition to the satisfactory completion of our due diligence on CardioGenics,
      we
      will be required to raise capital for the contemplated transaction through
      a
      combination of additional borrowings and the issuance of debt and equity
      securities. At this time, no such planned financing arrangements have commenced.




**Competition**




The
      market in which we are engaged is highly competitive. Established businesses
      in
      the health and pharmaceutical industries have longer operating histories,
      greater name recognition, more technical personnel and significantly greater
      financial and business resources than we do. Additionally, new competitors
      with
      potentially unique or more desirable products or services may continue to enter
      these sectors.




3




**Government
      Regulation**




Our
      targeted industries are heavily regulated by government regulations including
      those governed by the United States Food and Drug Administration (“FDA”). We are
      not aware of any existing or probable governmental regulation that will have
      an
      adverse material impact on us.




**Research
      and Development**




Our
      current business relies on entering the health and pharmaceutical sectors and
      as
      a result our Company expects to commence incurring research and development
      expenses to that end. We have not incurred research and development expenditures
      for the fiscal years ended December 31, 2006 and 2005.




**Employees**




As
      of
      December 31, 2006, the Company was managed by its Chief Executive Officer and
      Executive Vice President, and had one additional full time employee hired during
      the last quarter of 2006. Various management services, including
      word-processing, filing and bookkeeping services are outsourced to an affiliated
      company. During the year ended December 31, 2006, fees for such services
      amounted to approximately $34,000. However, we expect to add additional
      employees as needed in accordance with our future operating plans.




**Available
      Information**




Our
      electronic filings with the U.S. Securities and Exchange Commission (including
      our annual report on Form 10-KSB, quarterly reports on Form 10-QSB and current
      reports on Form 8-K, and any amendments to these reports) are available free
      of
      charge at www.sec.gov. The public may also read and copy any materials we file
      with the SEC at the SEC’s Public Reference Room at 450 Fifth Street,, N.W.,
      Washington, D.C. 20549. Information on the operation of the Public Reference
      Room can be obtained by calling the SEC at 1-800-SEC-0330. Such SEC filings
      will
      also be made available at our internet address, www.karverint.com, upon the
      completion of the construction of our website. We will voluntarily provide
      an
      annual report to shareholders upon their request and the annual report will
      include audited financial statements. All such requests should be directed
      to
      Dr. Jack Kachkar, Chief Executive Officer, at the office of the Company.




**RISK
      FACTORS**




The
      Company is subject to numerous risks. You should carefully review and consider
      the following risks as well as all other information contained in this report.
      Additional risks and uncertainties of which we are currently unaware or which
      we
      believe are not material could also impair our business.




**RISKS
      RELATED TO OUR BUSINESS**




***We
      continue to experience operating losses and will require financing to fulfill
      our business plan.***




We
      continue to experience operating losses. For the year ended December 31, 2006,
      we had a net loss of approximately $439,000 compared to a net loss of $286,000
      for the year ended December 31, 2005. See Item 7, “Management’s Discussion
      and Analysis of Financial Condition and Results of Operation” for further
      details on our operations.




Our
      business strategy is focused on corporate and product acquisitions in the
      pharmaceutical and health services industries. To date, we have not formally
      finalized any such transactions. Our business plan also requires us to raise
      capital for such contemplated transactions through a combination of borrowings
      and the issuance of debt and equity securities. At this time, no such financing
      transactions have been agreed to or finalized, and there is no assurance that
      we
      will be able to raise the capital we require to fulfill our business
      plan.




4




***We
      may be unable to obtain financing for the product or corporate acquisitions
      that
      are available to us.***




As
      we are
      a development stage company, we will require significant additional financial
      resources for the expansion of our health and pharmaceutical services business.
      Our current operations have been financed through stockholder loans. At this
      time, it is not possible to quantify what amount may actually be required and
      we
      will continue to depend on such loans from our stockholders. As required, we
      will attempt to obtain financing for acquisition opportunities through a
      combination of loans and equity investments from commercial sources, seller
      debt
      financing, issuance of our equity securities as part of the purchase price,
      and
      other sources. Commercial sources will tend to come from investment funds,
      private equity funds and other non-traditional sources, usually at a very high
      borrowing cost. Use of our equity securities could result in material dilution
      to our existing stockholders. There can be no assurance that we will be able
      to
      obtain adequate financing for further acquisitions or that, if available, such
      financing will be on favorable terms. If we are unable to obtain the required
      financings to implement our business strategies, our ability to conduct our
      business may be adversely affected.




***We
      must add management and personnel to implement our business plan.***




As
      of the
      date of this report, the Company is managed by its Chief Executive Officer
      and
      Executive Vice President, and has one additional full time employee. Various
      management services are outsourced to an affiliated company and such services
      are limited at this time. Any success we expect to have will therefore be
      heavily dependent on the addition and performance of executive officers,
      managers and personnel. Our growth and future success will depend, in large
      part, on the contributions of such individuals as well as our ability to
      motivate and retain these personnel. In addition, our proposed plan of
      development will require an increase in management, business, financial,
      scientific, sales and marketing personnel, and an investment in the professional
      development of the expertise of such employees and management. We are currently
      seeking senior management executives, and business, financial, and sales and
      marketing executives to join our Company. Due to both our limited operating
      history and current financial resources, there can be no assurance that we
      will
      be successful in recruiting and retaining all such personnel to help us
      implement our business plan, and operating and investment strategies. If we
      are
      unable to recruit and retain such management and personnel, our ability to
      implement our business plan may be adversely affected.




***Our
      ability to market our own proprietary pharmaceutical products or medical devices
      will face regulatory obstacles.***




Our
      Company is presently reviewing the feasibility of entering the immunoassay
      diagnostic niche market as it applies to cardiac ailments and disease, but
      to
      date, we have not yet commenced such activities. In addition, we are actively
      pursuing other pharmaceutical corporate and product acquisitions in order to
      establish a competitive position in that and other industries. Such product
      acquisitions including development stage pharmaceutical product or medical
      device acquisitions.




Approvals
      of new medical devices or pharmaceutical products is a time-consuming and very
      expensive process involving testing, clinical trials and approvals at various
      stages of the process by the U.S. Food & Drug Administration (“FDA”), the
      Canadian Therapeutic Products Directorate (“TPD”), the U.K. Medicines and
      Healthcare Products Regulatory Authority (“MHRA”), the European Agency for the
      Evaluation of Medicinal Products (“EMEA”), and other such regulatory agencies in
      jurisdictions where we expect to distribute our products or services.
      Additionally, such medical devices or products may also be subjected to patent
      review and possible disallowance. Our ability to obtain regulatory approval
      for
      our products will also require extensive testing, and we currently lack the
      resources to conduct such testing.




There
      is
      no assurance we can obtain all required regulatory approvals necessary to
      develop and commercialize our own pharmaceutical products or medical devices.
      Even if we successfully develop and commercialize a regulatory-approved
      pharmaceutical product or medical device, we may not be able to generate sales
      sufficient to create a profit or otherwise avoid a loss. As a result, there
      is a
      prolonged lead-time to begin the development and sale of such products, and
      therefore these products will not become available for sale in the foreseeable
      future. If we cannot successfully develop, commercialize and market our own
      pharmaceutical products or medical devices, due to the failure to obtain the
      necessary regulatory approvals to market such products, we would miss a
      strategic opportunity to grow our business.




5




Also,
      once our products are potentially developed, they cannot be marketed until
      the
      completion of extensive testing and field trials. We will require the help
      of
      other companies and consultants to perform some of the testing. At any stage
      of
      the testing process, there are the risks of injury to test subjects, and
      regulatory cessation of the process despite having invested significantly in
      the
      product, due to risk of harm, inefficacy of the products and many other reasons.
      In addition, we do not currently have the capital resources to begin the process
      of conducting testing and trials necessary to obtain any required regulatory
      approvals.




***If
      we are able to develop or acquire proprietary pharmaceutical products or medical
      devices, there is no assurance we can market them successfully.***




We
      do not
      have a sales force capable of marketing any pharmaceutical products or medical
      devices that we are able to develop and obtain approval for. We may either
      have
      to invest in creating such a sales force, attempt to create strategic marketing
      alliances with our existing customers and/or establish strategic marketing
      relationships with other companies in the industry.




***We
      have no guarantee of developmental success.***




Our
      Company or our potential investee companies and/or partners may not be able
      to
      find commercial opportunities for our planned products as it is impossible
      to
      ensure that any research and development we conduct or invest in will result
      in
      the creation of marketable or profitable products. We also currently lack the
      financial resources and business infrastructure to conduct such development
      work.




**RISKS
      RELATED TO OUR STOCK**




***We
      do not expect to pay dividends.***




We
      do not
      anticipate paying any cash dividends on our common stock in the foreseeable
      future. Furthermore, for the foreseeable future, we intend to retain profits,
      if
      any, to fund our planned growth and expansion.




***Shares
      that may be eligible for future sale may adversely affect the market price
      of
      our common stock.***




Sales
      of
      substantial amounts of common stock by shareholders in the public market are
      likely to adversely affect the market price of our common stock and could impair
      our ability to raise capital by selling equity securities.




***Our
      company is substantially controlled by our management team.***




As
      of
      March 26, 2007, the executive officers and directors of our Company and their
      family members, associates and their affiliates beneficially owned approximately
      62% of the shares of the currently outstanding common stock. Accordingly, and
      because there is no cumulative voting for directors, our executive officers
      and
      directors may be in a position to influence the election of all the directors
      of
      the Company and to control through their stock ownership the business of the
      Company.




6




***There
      is potential volatility in the price of our stock.***




The
      market price of the shares of our common stock, like the securities of many
      other over-the-counter traded companies may be highly volatile. Such price
      has
      ranged from $0.50 to $0.88 during the year ended December 31, 2006. See Item
      5,
“Market for Our Common Equity and Related Stockholder Matters and Small Business
      Issuer Purchases of Equity Securities.” Factors such as developments in our
      relationships with our customers, material adverse events to our customers,
      changes in FDA and other governmental regulations, market changes in the
      pharmaceutical industry, loss of key company executives, sales of large numbers
      of shares of our common stock by existing stockholders and general market
      conditions may have a significant effect on the market price of our common
      stock. In addition, U.S. stock markets have experienced extreme price and volume
      fluctuations in the past. This volatility has significantly affected the market
      prices of securities of many pharmaceutical and biotechnology companies, and
      companies such as ours in related industries, for reasons frequently unrelated
      or disproportionate to the operating performance of the specific companies.
      These broad market fluctuations may adversely affect the market price of our
      common stock.




**ITEM
      2.** **DESCRIPTION
      OF PROPERT** **Y**




We
      do not
      own any real estate. We are leasing our executive offices at 601 Brickell Key
      Drive, Suite 901, Miami, FL, 33131, which consist of approximately 3,000 square
      feet of space at an annual rent of approximately $66,000, net of a sub-lease
      with an affiliate. The lease expires on March 31, 2009.




**ITEM
      3.****LEGAL
      PROCEEDINGS******





We
      may be
      involved from time to time in legal proceedings and litigation incidental to
      the
      conduct of our business. As of December 31, 2006, there were no pending legal
      proceedings.




**ITEM
      4.** **SUBMISSION
      OF MATTERS TO A VOTE OF** **SECURITY
      HOLDERS**




No
      matters have been submitted to our security holders for a vote, through the
      solicitation of proxies or otherwise, during the fourth quarter of the fiscal
      year ended December 31, 2006.




7





**PART
        II**


**ITEM
                5.**
              **MARKET
                  FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS****AND SMALL BUSINESS ISSUER PURCHASES OF EQUITY
                  SECURITIES**


Our
      common stock trades on the Over-The-Counter Bulletin Board (“OTCBB”) under the
      symbol “KRVR.” The following table sets forth, for the fiscal quarters
      indicated, the high and low closing prices for our common stock, as reported
      by
      the OTCBB. The quotations reflect inter-dealer prices without retail mark-up,
      markdown or commission and may not represent actual transactions. We traded
      on
      the OTCBB from September 30, 2004 through November 14, 2005, under the symbol
      “MRXI.” We traded on the OTCBB from inception through September 29, 2004, under
      the symbol “CXTX”.




Quarter
                Ended
            
            High
            
            LowMarch,
                31, 2005
            
            $
            0.45
            
            $
            0.32June
                30, 2005
            
            $
            0.37
            
            $
            0.28September
                30, 2005
            
            $
            0.50
            
            $
            0.35December
                31, 2005
            
            $
            0.68
            
            $
            0.40March,
                31, 2006
            
            $
            0.80
            
            $
            0.50June
                30, 2006
            
            $
            0.81
            
            $
            0.53September
                30, 2006
            
            $
            0.88
            
            $
            0.71December
                31, 2006
            
            $
            0.88
            
            $
            0.70




**Holders**




On
      December 31, 2006, the closing sale price for our common stock, as reported
      by
      the Over-The-Counter Bulletin Board, was $0.70. As of December 31, 2006, our
      common stock was held by 32 holders of record.




**Dividends**




We
      have
      never paid cash dividends on our common stock and do not anticipate paying
      any
      cash dividends on our common stock in the foreseeable future.




**Recent
      Sales of Unregistered Securities**




During
      the year ended December 31, 2006, there were no sales of securities issued
      by
      the Company without registration under the Securities Act of 1933, as
      amended.




**Securities
      Authorized for Issuance under Equity Compensation Plans**




As
      a
      development stage company, we presently have no equity compensation
      plans.




**Transfer
      Agent and Registrar:**




Our
      transfer agent is StockTrans, Inc. of 44 West Lancaster Avenue, Ardmore, PA
      19003.




8




**ITEM
      6.****MANAGEMENT’S
      DISCUSSION AND ANALYSIS OR PLAN OF OPERATION**




We
      are an
      emerging health and pharmaceutical services company. Our Company is presently
      reviewing the feasibility of entering the immunoassay diagnostic niche market
      as
      it applies to cardiac ailments and disease, but to date, we have not yet
      commenced such activities. In addition, we are actively pursuing other
      pharmaceutical corporate and product acquisitions in order to establish a
      competitive position in that and other industries. Although we continue to
      pursue such opportunities, to date, we have not formally finalized any such
      transactions.




**CRITICAL
      ACCOUNTING POLICIES**




Our
      significant accounting policies are disclosed in Note 3 of the notes to the
      consolidated financial statements included in Item 7 of this Form
      10-KSB.




**RESULTS
      OF OPERATIONS**




The
      accompanying consolidated financial information includes the accounts of Karver
      and its wholly owned subsidiary, MDRX, since September 13, 2004, the date of
      the
      Share Exchange Agreement with
      that
      company and the transfer of our theater ticket operation to Aisle
      Seats.




**Operating
      Expenses**




Operating
      expenses for the year ended December 31, 2006, were approximately $405,000
      which
      included professional fees of approximately $193,000, travel and promotion
      expenses of approximately $2,000, rent expense of approximately $82,000, general
      office expenses of approximately $38,000, payroll and related expenses of
      approximately $86,000, and depreciation of furniture and equipment of
      approximately $4,400. In comparison, operating expenses for the year ended
      December 31, 2005, were approximately $274,000 which included professional
      fees
      of approximately $196,000, travel and promotion expenses of approximately
      $16,000, rent expenses of approximately $36,000, general office expenses of
      approximately $22,000 and depreciation of furniture and equipment of
      approximately $5,000. There were no payroll and related expenses for the year
      ended December 31, 2005.




**Loss
      before Interest Expense**




Loss
      before interest expense for the year ended December 31, 2006 increased by
      approximately $131,000 to $405,000 from $274,000 for the year ended December
      31,
      2005. The major reason for the increase relates to higher rent expense of
      approximately $46,000 due to the new office space in Miami, Florida, an increase
      of $16,000 in general office expense and a higher payroll expense of
      approximately $86,000 as the Company had no employees in the comparative period.




**Interest
      Expense**




Interest
      expense for the year ended December 31, 2006, was approximately $35,000 relating
      to accrued interest on the 7% stockholders loans received during the year.
      In
      comparison, interest expense for the year ended December 31, 2005, was
      approximately $12,000 also relating to the accrued interest on the 7%
      stockholders loans received during the year. The Company expects to incur such
      expenses until it starts generating cash flow from operations.




**Net
      Loss**




Net
      losses for the years ended December 31, 2006 and 2005, were approximately
      $439,000 and $286,000 respectively. The
      losses were the result of operating expenses of $405,000 and $274,000,
      respectively.




9




**LIQUIDITY
      AND CAPITAL RESOURCES**




At
      December 31, 2006, we had cash of approximately $1,000.




Since
      our
      sale of the theater ticket business, we have been financing our operations
      primarily through capital contributions and short term loans from our
      stockholders. During the year ended December 31, 2006, net funding provided
      by
      stockholder amounted to approximately $ 539,000
      and these funds were paid directly by the stockholder on behalf of the Company.
      The Company recorded the related expenses and increased the stockholder loan
      to
      approximately $765,000.




As
      we are
      a development stage company, we will require significant additional financial
      resources for the expansion of our health and pharmaceutical services business.
      At this time, it is not possible to quantify what amount may actually be
      required and we will continue to depend on loans from our stockholders. If
      required, we may seek to obtain additional financing through public or private
      equity financings although no specific plans exist for conducting such
      financings at this time. If we are unable to obtain the required financings
      to
      implement our business strategies, our ability to conduct our business may
      be
      adversely affected.




We
      are
      also actively pursuing acquisitions that may require substantial capital
      resources. In the event that we make a significant future acquisition or change
      our capital structure, we may also be required to raise additional funds through
      additional borrowings or the issuance of additional debt or equity
      securities.




**Operating
      Activities**




The
      net
      cash provided from operating activities for the year ended December 31, 2006,
      amounted to approximately $42,000. For the year ended December 31, 2006, the
      net
      cash provided by operations was primarily the result of fundings provided by
      a
      stockholder of approximately $539,000 and a net loss of approximately $439,000
      adjusted by a depreciation expense of approximately $4,400. These amounts were
      additionally offset by an increase in prepaid expenses and other current assets
      of approximately $20,000, an increase in deposits of approximately $28,000,
      a
      decrease in accounts payable and other current liabilities of approximately
      $88,000, a decrease in due to affiliate of approximately $46,000, an increase
      in
      due to related parties of approximately $81,000 and an increase in accrued
      stockholder interest of $33,000




In
      comparison, the net cash provided from operating activities for the year ended
      December 31, 2005 amounted to $283. For the year ended December 31, 2005, the
      net cash provided by the operations was primarily the result of a net loss
      of
      approximately $286,000 adjusted by depreciation expense of approximately $5,000
      and an increase in prepaid expenses of approximately $21,000, off-set by
      increase in non-cash fundings provided by stockholder of approximately $141,000,
      an increase in accounts payable and accrued liabilities amounting to
      approximately $70,000, an increase in due to affiliate of $36,000, an increase
      in due to related parties of $43,000 and an increase in accrued stockholder
      interest of approximately $12,000.




**Investing
      Activities**




The
      net
      cash used in investing activities for the year ended December 31, 2006, amounted
      to approximately $37,000. In comparison, for the year ended December 31, 2005,
      no cash was used in investing activities




**Financing
      Activities**




No
      cash
      was used in or provided by financing activities for the years ended December
      31,
      2006 and 2005.




10




**Subsequent
      Events**




On
      February 8, we signed a term sheet for a proposed acquisition of all the
      outstanding shares of common stock of Gemoscan International, Inc., a
      Toronto-based company engaged in diagnosing and providing solutions for
      treatment of food intolerances. The proposed acquisition was subject to several
      conditions, including completion of due diligence and execution of definitive
      documentation for the transaction. On March 16, 2007, the proposed acquisition
      was terminated by the parties, which executed a mutual general release.




**Going
      Concern**




As
      shown
      in the accompanying consolidated financial statements, we incurred substantial
      net losses for the cumulative period from September 13, 2004 (effective date
      of
      Development Stage Company) through December 31, 2006, and an accumulated deficit
      of approximately $1.0 million as at December 31, 2006. There is no
      guarantee that we will be able to generate revenue or raise capital to
      support the Company’s operations. This raises substantial doubt about our
      ability to continue as a going concern.




Our
      future success is dependent upon continued financial support from our
      stockholders, the attainment of financing necessary to operate our business
      including completing any potential acquisitions, and achievement of profitable
      operations upon additional financing.




Management
      believes that actions presently being taken to obtain additional equity or
      debt
      financing to fund its operations and implement its strategic business plans
      to
      provide the opportunity for the Company to continue as a going concern. This
      includes management’s ability to rely on existing financial industry
      relationships to raise enough capital for the Company prior to the end of 2007,
      although there can be no assurances that it will be able to
      raise sufficient capital to generate revenues to sustain
      operations.




The
      consolidated financial statements do not include any adjustments relating to
      the
      recoverability or classification of recorded assets and liabilities that might
      result should we not be able to continue as a going concern.




**Off-Balance
      Sheet Arrangements**




We
      do not
      have any off balance sheet arrangements that have or are reasonably likely
      to
      have a current or future effect on our financial condition, changes in financial
      condition, revenues or expenses, result of operations, liquidity, capital
      expenditures or capital resources that is material to investors.




11




**ITEM
      7.**  **FINANCIAL
      STATEMENTS**





**INDEX
      TO CONSOLIDATED FINANCIAL STATEMENTS**


Report
                  of Berkovits, Lago and Company, LLP, Independent Registered Public
                  Accounting Firm
              
              
              F-2Consolidated
                  Balance Sheet
              
              
              F-3Consolidated
                  Statements of Operations
              
              
              F-4Consolidated
                  Statements of Changes in Stockholders’ Deficit
              
              
              F-5Consolidated
                  Statements of Cash Flows
              
              
              F-6Notes
                  to Consolidated Financial Statements
              
              
              F-7




F-1




**REPORT
      OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**


To
        the
        Board of Directors
 Karver
        International, Inc.
 
 We
        have
        audited the accompanying consolidated balance sheet of Karver International,
        Inc. (a development stage company) (formerly known as Medeorex, Inc.) as
        of
        December 31, 2006, and the related consolidated statements of operations,
        changes in stockholders’ deficit and cash flows for the years ended December 31,
        2006 and 2005 and for the period from September 13, 2004 (inception)
        to December 31, 2006. These consolidated financial statements are the
        responsibility of the Company’s management. Our responsibility is to express an
        opinion on these consolidated financial statements based on our
        audits.
 
 We
        conducted our audits in accordance with the standards of the Public Company
        Accounting Oversight Board (United States). Those standards require that
        we plan
        and perform the audit to obtain reasonable assurance about whether the financial
        statements are free of material misstatement. The Company has determined
        that it
        is not required to have, nor were we engaged to perform, an audit of its
        internal control over financial reporting. Our audits included consideration
        of
        internal control over financial reporting as a basis for designing audit
        procedures that are appropriate in the circumstances, but not for the purpose
        of
        expressing an opinion on the effectiveness of the Company’s internal control
        over financial reporting. Accordingly, we do not express such an opinion.
        An
        audit also includes examining, on a test basis, evidence supporting the amounts
        and disclosures in the financial statements. An audit also includes assessing
        the accounting principles used and significant estimates made by management,
        as
        well as evaluating the overall financial statement presentation. We believe
        that
        our audits provide a reasonable basis for our opinion.
 
 In
        our
        opinion, the consolidated financial statements referred to above present
        fairly,
        in all material respects, the consolidated financial position of Karver
        International, Inc. (a developmental stage company) (formerly known as Medeorex,
        Inc.) as of December 31, 2006, and the results of operations and cash flows
        for
        the years ended December 31, 2006 and 2005 and for the period from September
        13,
        2004 (inception) to December 31, 2006 in conformity with accounting principles
        generally accepted in the United States of America.
 
 The
        accompanying consolidated financial statements have been prepared assuming
        that
        the Company will continue as a going concern. As discussed in Note 2 to the
        consolidated financial statements, the Company’s dependence on outside
        financing, lack of sufficient working capital, and recurring losses from
        operations in the development stage raise substantial doubt about the Company’s
        ability to continue as a going concern. Management’s plans are described in Note
        2 to the consolidated financial statements. The consolidated financial
        statements do not include any adjustments that might result from the outcome
        of
        this uncertainty.
 
 
 /s/
        Berkovits, Lago & Company, LLP
 Fort
        Lauderdale, Florida
 March
        15,
        2007


F-2





**KARVER
      INTERNATIONAL, INC.**


**(A
      Development Stage Company)**


**Consolidated
      Balance Sheet for December 31, 2006**


**Assets**Current
                  assets:Cash
                  and cash equivalents
              
              **$**
              **1,236**Prepaid
                  expenses
              
              
              **41,007**Total
                  current assets
              
              
              **42,243**Furniture
                  and equipment, net
              
              
              **37,978**Other
                  assets- deposits
              
              
              **28,270****66,248**Total
                  assets
              
              **$**
              **108,491****Liabilities
                  and Stockholders' Deficit**Current
                  liabilities:Accounts
                  payable
              
              **$**
              **11,101**Due
                  to affiliated company
              
              
              **6,420**Due
                  to related parties
              
              
              **124,167**Accrued
                  liabilities
              
              
              **29,500**Accrued
                  interest on stockholder loan
              
              
              **44,670**Stockholder
                  loans at 7% interest per annum, due on demand
              
              
              **764,558**Total
                  current liabilities
              
              
              **980,416**Commitments
                  and contingenciesStockholders’
                  deficit:Preferred
                  stock - $0.0001 par value, 10,000,000 shares authorized-0-
                  shares issued and outstanding
              
              
              **-**Common
                  stock - $0.0001 par value, 20,000,000 shares authorized, 13,641,461
                  shares
                  issued and outstanding as of December 31, 2006
              
              
              **1,364**Additional
                  paid-in capital
              
              
              **214,531**Accumulated
                  deficit prior to development stage
              
              
              **(66,003**
              **)**Accumulated
                  deficit during development stage
              
              
              **(1,021,817**
              **)**Total
                  stockholders’ deficit
              
              
              **(871,925**
              **)**Total
                  liabilities and stockholders’ deficit
              
              **$**
              **108,491**




The
      accompanying notes are an integral part of these consolidated financial
      statements.




F-3


**KARVER
      INTERNATIONAL, INC.**


**(A
      Development Stage Company)**


**Consolidated
      Statements of Operations**


**For
                  the Years Ended December 31,**
              
              **Cumulative
                  Period from September 13, 2004 (Effective date of Development Stage
                  Company) to****2006**
              
              **2005**
              
              **December
                  31, 2006**Operating
                  expensesProfessional
                  fees
              
              **$**
              **192,976**
              
              $
              195,594
              
              $
              538,948Travel,
                  promotion and related expenses
              
              
              **2,068**
              
              
              15,756
              
              
              136,262Rent
                  expense
              
              
              **81,958**
              
              
              36,000
              
              
              132,958General
                  office expenses
              
              
              **37,315**
              
              
              21,941
              
              
              68,555Payroll
                  and related expenses
              
              
              **86,058**
              
              
              -
              
              
              86,058Depreciation
              
              
              **4,451**
              
              
              5,053
              
              
              10,766Total
                  operating expenses
              
              
              **404,826**
              
              
              274,344
              
              
              973,547Loss
                  before interest expense
              
              
              **(404,826**
              **)**
              
              (274,344
              )
              
              (973,547
              )Interest
                  expense
              
              
              **(34,615**
              **)**
              
              (12,055
              )
              
              (48,270
              )Net
                  loss
              
              **$**
              **(439,441**
              **)**
              $
              (286,399
              )
              $
              (1,021,817
              )Basic
                  and fully diluted net loss per share
              
              **$**
              **(0.03**
              **)**
              $
              (0.02
              )Weighted-average
                  number of shares used in computing basic and fully diluted net
                  loss per
                  share
              
              
              **13,641,461**
              
              
              14,083,984





The
      accompanying notes are an integral part of these consolidated financial
      statements.




F-4




**KARVER
      INTERNATIONAL, INC.**


**(A
      Development Stage Company)**


**Consolidated
      Statement of Changes in Stockholders’ Deficit**


Common
                    Stock
                
                
                
                Accumulated
                    DeficitShares
                
                Amount
                
                Additional
                    Paid-In Capital
                
                Prior
                    to Development Stage
                
                During
                    Development Stage
                
                TotalBalances
                    at December 31, 2004
                
                
                14,718,266
                
                $
                1,472
                
                $
                214,531
                
                $
                (66,003
                )
                $
                (295,977
                )
                $
                (145,977
                )Shares
                    returned to treasury (MedLink Parties)
                
                
                (1,076,805
                )
                
                (108
                )
                
                -
                
                
                -
                
                
                -
                
                
                (108
                )Net
                    loss for the period
                
                
                -
                
                
                -
                
                
                -
                
                
                -
                
                
                (286,399
                )
                
                (286,399
                )Balances
                    at December 31, 2005
                
                
                13,641,461
                
                
                1,364
                
                
                214,531
                
                
                (66,003
                )
                
                (582,376
                )
                
                (432,484
                )Net
                    loss for the period
                
                
                -
                
                
                -
                
                
                -
                
                
                -
                
                
                (439,441
                )
                
                (439,441
                )Balances
                    at December 31, 2006
                
                
                13,641,461
                
                $
                1,364
                
                $
                214,531
                
                $
                (66,003
                )
                $
                (1,021,817
                )
                $
                (871,925
                )


The
      accompanying notes are an integral part of these consolidated financial
      statements.




F-5


**KARVER
      INTERNATIONAL, INC.**


**(A
      Development Stage Company)**


**Consolidated
      Statements of Cash Flows**


**For
                  the Years Ended December 31,**
              
              **Cumulative
                  Period from September 13,
                  2004 (Effective Date of Development Stage Company)
                  through****2006**
              
              **2005**
              
              **December
                  31, 2006**Cash
                  flows from operating activities:Net
                  loss for the period
              
              **$**
              **(439,441**
              **)**
              $
              (286,399
              )
              $
              (1,021,817
              )Adjustments
                  to reconcile net loss to net cash used in operating
                  activities:Depreciation
              
              
              **4,451**
              
              
              5,053
              
              
              10,766Fundings
                  provided by stockholder
              
              
              **539,195**
              
              
              141,206
              
              
              764,558Shares
                  returned to treasury
              
              
              **-**
              
              
              (108
              )
              
              (108
              )Changes
                  in assets and liabilities:Increase
                  in prepaid expenses and other current assets
              
              
              **(20,363**
              **)**
              
              (20,645
              )
              
              (41,007
              )Increase
                  in deposits
              
              
              **(28,270**
              **)**
              
              -
              
              
              (28,270
              )(Decrease)/Increase
                  in accounts payable and other current liabilities
              
              
              **(87,862**
              **)**
              
              70,428
              
              
              55,601(Decrease)/increase
                  in due to affiliate
              
              
              **(44,580**
              **)**
              
              36,000
              
              
              (8,580
              )Increase
                  in due to related party
              
              
              **81,167**
              
              
              43,000
              
              
              124,167Increased
                  in accrued stockholder interest
              
              
              **32,922**
              
              
              11,748
              
              
              44,670Net
                  cash provided by (used in) operating activities
              
              
              **37,219**
              
              
              283
              
              
              (90,020
              )Cash
                  flows from investing activities:Purchases
                  of furniture and equipment
              
              
              **(****36,644**
              **)**
              
              -
              
              
              (48,744
              )Net
                  cash used in investing activities
              
              
              **(36,644**
              **)**
              
              -
              
              
              (48,744
              )Cash
                  flows from financing activities:Proceeds
                  from share issuance
              
              
              **-**
              
              
              -
              
              
              150,000Net
                  cash provided by financing activities
              
              
              **-**
              
              
              -
              
              
              150,000Change
                  in cash
              
              
              **575**
              
              
              283
              
              
              1,236Cash
                  at beginning of period
              
              
              **661**
              
              
              378
              
              
              -Cash
                  at end of period
              
              **$**
              **1,236**
              
              $
              661
              
              $
              1,236**Supplemental
                  Disclosure of Cash Flow Information:**Non-cash
                  financing activities:Shares
                  returned to treasury
              
              **$**
              **-**
              
              $
              (108
              )
              $
              (108
              )Expenses
                  paid by stockholders on behalf of Company
              
              
              **539,195**
              
              
              141,206
              
              
              764,558Increase
                  in stockholder loan
              
              
              **(539,195**
              **)**
              
              (141,206
              )
              
              (764,558
              )




The
      accompanying notes are an integral part of these consolidated financial
      statements.




F-6


**KARVER
      INTERNATIONAL, INC.**


**(A
      Development Stage Company)**


**NOTES
      TO CONSOLIDATED FINANCIAL STATEMENTS**





**Not** **e
      1****.****Business
      Description and Presentation**




Karver
      International, Inc. (“Karver”) was incorporated on April 18, 1989, in the State
      of New York and had been engaged in the theater ticket business. On September
      13, 2004, pursuant to a Share Exchange Agreement with MDRX, Inc. (f/k/a
      Medeorex, Inc.), a privately held Delaware corporation established with the
      intention of operating in the health and pharmaceutical services industries,
      the
      stockholders of MDRX were issued an aggregate of 4,490,226 shares of the
      Company’s stock in exchange for all of the issued and outstanding shares of
      MDRX. Pursuant to the Share Exchange Agreement, MDRX became a wholly owned
      subsidiary of the Company and Clixtix changed its name to Medeorex, Inc.
      Immediately following the closing under the MDRX Share Exchange Agreement,
      the
      Company transferred its theater ticket operations to Aisle Seats, Inc., a
      company controlled by the Company’s former president and majority stockholder.
      As consideration, Aisle Seats assumed the net liabilities of the theater ticket
      business operation.




On
      November 3, 2005, the Company changed its name to Karver International, Inc.




Since
      September 13, 2004, the Company’s activities principally consisted of seeking to
      aquire a business in the health and pharmaceuticals industries. Accordingly,
      the
      Company is considered to be in the development stage as defined by Statement
      of
      Financial Accounting Standards No. 7, “ *Accounting
      and Reporting by Development Stage Enterprise* s”.
      The
      Company operates in one business segment.




**Not** **e
      2.****Going
      Concern**




These
      financial statements have been prepared on a going concern basis and, as such,
      it has been assumed that the Company will be able to realize its assets and
      discharge its liabilities in the normal course of business. The Company has
      incurred substantial net losses from operations for the period from September
      13, 2004, (effective date as a development stage company) through December
      31,
      2006, and an accumulated deficit of approximately $1.0 million as at December
      31, 2006. There is no guarantee that we will be able to generate revenue or
      raise capital to continue to support the Company’s operations.  This raises
      substantial doubt about our ability to continue as a going concern.




Our
      future success is dependent upon continued financial support from our
      stockholders, the attainment of financing necessary to operate our business,
      including completing any potential acquisitions, and achievement of profitable
      operations upon additional financing. Management believes that actions presently
      being taken to obtain additional equity or debt financing to fund its operations
      and implement its strategic business plans should provide the opportunity
      for the Company to continue as a going concern. This includes management’s
      ability to rely on existing financial industry relationships to raise capital
      for the Company prior to the end of 2007, although there can be no
      assurances that it will be able to raise sufficient
      capital to generate revenues to sustain operations.




These
      financial statements do not include any adjustments relating to the
      recoverability of assets and classification of liabilities or any other
      adjustments that might be necessary should the Company be unable to continue
      as
      a going concern.




The
      consolidated financial statements do not include any adjustments relating to
      the
      recoverability or classification of recorded assets and liabilities that might
      result should we not be able to continue as a going concern.




**Note** **3.****Summary
      of Significant Accounting Policies**




*Consolidation*




F-7




The
      accompanying consolidated financial statements include the accounts of Karver
      and its wholly owned subsidiary MDRX, Inc.




All
      inter-company accounts and transactions have been eliminated in
      consolidation




*Use
      of Estimates*




The
      financial statements are prepared in conformity with accounting principles
      generally accepted in the United States of America. The preparation of financial
      statements, in conformity with generally accepted accounting principles,
      requires management to make estimates and assumptions. Those estimates and
      assumptions affect the reported amounts of assets and liabilities, the
      disclosure of contingent assets and liabilities, and the reported amounts of
      revenues and expenses. Actual results could differ from those
      estimates.




*Property
      and equipment, net*




Property
      and equipment consist of computer hardware and software. Property and equipment
      are recorded at costs less accumulated depreciation. Depreciation is calculated
      over the useful life of the assets using the straight line method.




*Net
      Loss per Share*




The
      Company follows the guidelines of Statement of Financial Accounting Standards
      No. 128, “ *Earnings
      per Share* ”
(“SFAS
      No.128”) in calculating its loss per share. SFAS No.128 states that basic and
      diluted earnings per share are based on the weighted average number of shares
      of
      common stock and potential common stock outstanding during the period. Potential
      common stock equivalents for purposes of determining diluted earnings per share
      include the effects of dilutive stock options, warrants and convertible
      securities. The effect on the number of shares of such potential common stock
      equivalents is computed using the treasury stock method or the if-converted
      method, as applicable. The Company has no outstanding options and warrants
      to
      dilute the calculation of net loss per share.




*Income
      Taxes*




The
      Company follows Statement of Financial Accounting Standards No. 109 *“Accounting
      for Income Taxes”* (“SFAS
      No. 109”) *.* Under
      the
      asset and liability method of SFAS No. 109, deferred tax assets and liabilities
      are recognized for the future tax consequences attributed to differences between
      the financial statements carrying amounts of existing assets and liabilities
      and
      their respective tax base. Deferred tax assets and liabilities are measured
      using enacted tax rates expected to apply to taxable income in the years in
      which those temporary differences are expected to be recovered or settled.
      Under
      SFAS No. 109, the effect on deferred tax assets and liabilities of a change
      in
      tax rates is recognized in income in the period that includes the enactment
      date.  If
      it is
      more likely than not that some portion of a deferred tax asset will not be
      realized, a valuation allowance is recognized.




*Recently
      Issued Accounting Standards*




In
      June
      2006, the FASB issued FASB Interpretation (“FIN”) No. 48 “Accounting for
      Uncertainty in Income Taxes—an interpretation of FASB Statement 109”.
      FIN 48 establishes a single model to address accounting for uncertainty in
      tax positions. FIN 48 clarifies the accounting for income taxes by
      prescribing a minimum recognition threshold a tax position is required to meet
      before being recognized in the financial statements. FIN 48 also provides
      guidance on derecognition, measurement, classification, interest and penalties,
      accounting in interim periods, disclosure and transition. FIN 48 is
      effective for fiscal years beginning after December 15, 2006. Company is
      currently assessing the impact of FIN 48 on its consolidated financial position
      and results of operations.




In
      September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements” (SFAS
      No. 157). SFAS No. 157 establishes a common definition for fair value
      to be applied to US GAAP requiring use of fair value, establishes a framework
      for measuring fair value, and expands disclosure about such fair value
      measurements. SFAS No. 157 is effective for fiscal years beginning after
      November 15, 2007. The Company is currently assessing the impact of SFAS
      No. 157 on its consolidated financial position and results of
      operations.




F-8




In
      September 2006, the FASB issued SFAS No. 158, “Employers' Accounting for Defined
      Benefit Pension and Other Postretirement Plans” (SFAS No. 158). SFAS No. 158
      requires that employers recognize on a prospective basis the funded status
      of
      their defined benefit pension and other postretirement benefit plans on their
      consolidated balance sheet and recognize as a component of other comprehensive
      income (loss), net of tax, the gains or losses and prior service costs or
      credits that arise during the period but are not recognized as components of
      net
      periodic benefit cost. We adopted SFAS No. 158 as of December 31, 2006. The
      implementation of this standard will not have any material impact on the
      Company’s consolidated financial position or results of operations.




In
      February, 2007, the FASB issued SFAS No. 159 “The Fair Value Option for
      Financial Assets and Financial Liabilities (SFAS No. 159). SFAS No. 159 permits
      entities to choose to measure many financial assets and financial liabilities
      at
      fair value. Unrealized gains and losses on items for which the fair value option
      has been elected are reported in earnings. SFAS No. 159 is effective for fiscal
      years beginning after November 15, 2007. The Company is currently assessing
      the impact of SFAS No. 159 on its consolidated financial position and results
      of
      operations.




In
      September 2006, the FASB issued FASB Staff Position (“FSP”) AUG AIR-1
“Accounting for Planned Major Maintenance Activities” (FSP AUG AIR-1). FSP AUG
      AIR-1 amends the guidance on the accounting for planned major maintenance
      activities; specifically it precludes the use of the previously acceptable
      “accrue in advance” method. FSP AUG AIR-1 is effective for fiscal years
      beginning after December 15, 2006. The implementation of this standard will
      not have a material impact on the Company’s consolidated financial position or
      results of operations.




In
      September 2006, the SEC staff issued Staff Accounting Bulletin (“SAB”) 108
“Considering the Effects of Prior Year Misstatements when Quantifying
      Misstatements in Current Year Financial Statements” (SAB 108). SAB 108 requires
      that public companies utilize a “dual-approach” to assessing the quantitative
      effects of financial misstatements. This dual approach includes both an income
      statement focused assessment and a balance sheet focused assessment. The
      guidance in SAB 108 must be applied to annual financial statements for fiscal
      years ending after November 15, 2006. The adoption of SAB 108 did not have
      a material effect on our consolidated financial position or results of
      operations.




Certain
      amounts from prior year consolidated financial statements and related notes
      have
      been reclassified to conform to the current year presentation.




**Not** **e
      4.****Furniture
      and Equipment**




Furniture
      and equipment **** consist
      of the following:




**December
                31, 2006**
            
            **December
                31, 2005**Office
                furniture and equipment
            
            **$**
            **7,929**
            
            $
            5,985Leasehold
                improvements
            
            
            **2,183**
            
            
            -Computer
                software
            
            
            **6,115**
            
            
            6,115**16,227**
            
            
            12,100Less
                accumulated depreciation
            
            
            **(10,766**
            **)**
            
            (6,315
            )**5,461**
            
            
            5,785Equipment
                installation in progress
            
            
            **32,517**
            
            
            -**$**
            **37,978**
            
            $
            5,785




F-9




For
      the
      year ended December 31, 2006, depreciation of furniture and equipment was
      approximately $4,400. In comparison, for the year ended December 31, 2005,
      depreciation of furniture and equipment was approximately $5,000.




**Not** **e
      5.****Stockholders’
      Deficit**




On
      May
      30, 2005, the Company returned 1,076,805 shares of the Company’s common stock,
      par value $0.0001 per share to treasury in conjunction with the agreement and
      general release terminating its relationship with MedLink Central, Inc. and
      four
      other stockholders as originally documented in the Asset Purchase Agreement
      dated August 2, 2004. These shares were subsequently cancelled by the
      Company.




**Note** **6.****Related
      Party Transactions**




During
      the year ended December 31, 2006, the Company accrued management fees of
      $41,000, payable to an affiliated company for management services. Additionally,
      the Company accrued rent expense of approximately $26,000, also payable to
      the
      affiliated company for the rental of furnished office space in NewYork City
      under a sublease agreement, which was terminated August 31, 2006. These amounts
      are included in the general and administrative expenses of the Company’s
      consolidated statement of operations. At December 31, 2006, the total amount
      due
      to the affiliated company was approximately $6,000. The Company settles the
      outstanding amounts on a monthly basis.




During
      the year ended December 31, 2006, the Company entered into a short-term lease
      agreement with the same affiliated company whereby commencing September 1,
      2006,
      the Company agreed to sublease a portion of its office space in Miami, Florida,
      to the affiliate through March 31, 2007, for monthly rent income of $4,000.
      Subsequently upon maturity of the agreement, the sublease was
      extended for an additional one year period. Prior to September 1,
      2006, the Company had leased this office space on a month to month basis for
      monthly rent income of $2,500. For the year ended December 31, 2006, the Company
      charged approximately $36,000 for sublease rental income on this office space.
      Rent income is included in the consolidated statement of operations as an offset
      against rent expense.




Additionally,
      for the year ended December 31, 2006, the Company accrued professional fees
      relating to accounting and administrative support services provided by related
      parties (consultants related to the Company) amounting to approximately $70,000.
      These amounts are included as professional fees on the Company’s consolidated
      statement of operations. The total amount due to related parties was
      approximately $124,000 at December 31, 2006.




The
      Company’s Chairman and Chief Executive Officer provides funding on an ongoing
      basis for working capital requirements. At December 31, 2006, the total amount
      owing to the Chairman and Chief Executive Officer was approximately $765,000
      and
      is repayable on demand. The Company’s Chairman and Chief Executive Officer has
      agreed not to seek repayment of this loan for a minimum of 12 months from
      December 31, 2006. The Company accrues interest on such outstanding amount
      at 7%
      per annum and at December 31, 2006, such accrued interest was approximately
      $45,000.




**Note** **7****.****Deferred
      Income Taxes**




At
      December 31, 2006, the Company had carryforward losses for income tax purposes
      of approximately $811,000 based on the federal income tax rate of 35% that
      may
      be offset against future taxable income. The carryforward losses expire at
      various times through the year 2021. Due to the uncertainty regarding the
      success of the future operations, management has recorded a valuation allowance
      against the deferred tax asset, which amounts to 100% of the related deferred
      tax asset.




**Note
      8.**  **Commitments
      and Contingencies**




The
      Company has commitments under an operating lease agreement for furnished office
      space in Miami, Florida. In addition to rent, the Company and its subsidiary
      is
      responsible for operating costs, real estate taxes and insurance.




As
      of
      December 31, 2006, the future minimum annual rental commitment under this lease,
      which expires on March 31, 2009, is as follows:




Year
                ending December 31, 2007
            
            $
            114,000Year
                ending December 31, 2008
            
            
            117,000Year
                ending December 31, 2009
            
            
            30,000$
            261,000




F-10




Rent
      expense under operating leases were approximately $82,000 and $36,000 for the
      years ended
      December 31, 2005 and 2004, respectively.




On
      May 6,
      2005, we agreed to acquire a minority interest in CardioGenics, Inc.
      (“CardioGenics”), a privately held Canadian biotechnology and medical devices
      company, subject to successful completion of the due diligence process.
      CardioGenics is focused on the development of superior products for the
      In-Vitro-Diagnostics cardiac testing market and several other related
      proprietary technologies related to the screening and testing of cardiac
      ailments. The terms of this potential investment were subsequently modified
      by
      both parties on June 14, 2005, on February 24, 2006, and again on February
      2007
      respectively furthermore on March 1, 2007 the parties agreed to extend the
      closing date to June 30, 2007.




Based
      on
      current terms, and subject to the satisfactory completion of due diligence
      and
      pursuant to a number of conditions being met by CardioGenics, the Company has
      agreed to potentially invest $2.5 million in the form of a private placement
      in
      voting convertible preferred stock of CardioGenics pursuant to which the Company
      will own approximately 20% of CardioGenics by the end of June 2007.
      Additionally, in return for the Karver investment and in order for Karver to
      obtain a majority control of CardioGenics as the Company may require,
      CardioGenics agreed to grant Karver a two-year warrant to purchase sufficient
      additional shares at a pre-set valuation to acquire a majority control of
      CardioGenics. In addition to the successful completion of its due diligence
      on
      CardioGenics, in order to complete the investment, Karver will be required
      to
      raise capital for the contemplated transaction through a combination of
      additional borrowings and the issuance of debt and equity securities. At this
      time, no such financing transactions have been agreed to or finalized.




In
      addition to the satisfactory completion of our due diligence on CardioGenics,
      we
      will be required to raise capital for the contemplated transaction through
      a
      combination of additional borrowings and the issuance of debt and equity
      securities. At this time, no such planned financing arrangements have commenced.




F-11




**ITEM
              8.**
            **CHANGES
                IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
                DISCLOSURE**




During
      the two most recent fiscal years, the Registrant has not had any disagreements
      with the auditor on any matter of accounting principles or practices, financial
      statement disclosure or auditing scope or procedures that would require
      disclosure in this Annual Report on Form 10-KSB.




**ITEM
      8A.****CONTROLS
      AND PROCEDURES**




We
      maintain disclosure controls and procedures designed to ensure that information
      required to be disclosed in reports filed under the Securities Exchange Act
      of
      1934, as amended, is recorded, processed, summarized and reported within the
      specified time period.




Our
      Chief
      Executive Officer and Principal Financial Officer has evaluated the
      effectiveness of our controls and procedures related to our reporting and
      disclosure obligations as of December 31, 2006, which is the end of the period
      covered by this Annual Report on Form 10-KSB. Based on that evaluation, our
      Chief Executive Officer and Principal Financial Officer concluded that our
      disclosure controls and procedures are effective.




There
      were no changes that occurred during the fiscal year ended December 31, 2006,
      that have materially affected, or are reasonable likely to materially affect,
      our internal controls over financial reporting.




**ITEM
      8B.** **OTHER
      INFORMATION**




None.




12




**PART**  **III**


**ITEM
                9.**
              **DIRECTORS,
                  EXECUTIVE OFFICERS, PROMOTERS, CONTROL PERSONS AND CORPORATE GOVERNANCE;
                  COMPLIANCE WITH SECTION 16(****a)
                  OF THE EXCHANGE ACT**




The
      members of our board of directors serve for one year terms and serve until
      their
      successors have been elected. The officers serve at the pleasure of the board
      of
      directors. Information as to our current directors and executive officers is
      as
      follows:




**Name**
            
            **Age**
            
            **Positions
                with the Company**Dr.
                Jack Kachkar
            
            44
            
            Chairman,
                Chief Executive Officer and President, Secretary, Principal Financial
                Officer and DirectorJay
                M. Green
            
            58
            
            Executive
                Vice President and Director





**Dr.
      Jack Kachkar** **MD** ,
      age 44,
      has been the Chairman, Chief Executive Officer and President, Secretary,
      Principal Financial Officer and a Director of the Company since September 2004.
      Dr. Kachkar is also the Chairman, Chief Executive Officer and Director of Inyx,
      Inc., a publicly traded specialty pharmaceutical company (“Inyx”) which is
      listed on the Nasdaq Over-the-Counter Bulletin Board. Dr.
      Kachkar also manages his family’s investments in the commodity industries.Dr. Kachkar is a medical doctor with experience as an executive within
      the pharmaceutical and health industries. In addition to his experience in
      providing consulting and advisory services within these industries, Dr. Kachkar
      has founded and assisted in the acquisition of a number of pharmaceutical
      companies focused on the commercialization and manufacturing of pharmaceutical
      products, including Inyx. From
      1996
      until December 2002, Dr. Kachkar was President and CEO of Miza Pharmaceuticals,
      Inc. (“Miza”), a Canadian corporation in Toronto, Ontario. Miza is now inactive.
      While in operation, Miza had three operating subsidiaries, Miza Pharmaceuticals
      (UK), Ltd. (“Miza UK”), Miza Ireland Limited (“Miza Ireland”) and Miza
      Pharmaceuticals USA, Inc. (“Miza USA”). Dr. Kachkar was involved in the
      management of all four companies, although he resigned as an officer of Miza
      in
      December 2002 and as a director in May 2003, prior to that company becoming
      inactive; he resigned as a director of Miza UK in August 2002 and was never
      an
      officer; he resigned as a director of Miza Ireland in October 2002 and was
      never
      an officer; and he resigned as an officer of Miza USA in March 2003 and as
      a
      director in April 2003. Miza UK was placed in Administration in September 2002,
      and sold its assets out of Administration in March 2003, to Inyx Pharma; Miza
      Ireland’s assets were sold by a court-appointed liquidator during 2003; Miza USA
      was placed into Chapter 11 bankruptcy proceedings by its new owners in May
      2003 under the name Carr Pharmaceuticals, Inc., and was then subsequently
      liquidated by its secured lenders. Dr. Kachkar earned his medical degree *summa
      cum laude* in 1995
      from the English Language Medical Program at Semmelweis Medical University
      in
      Budapest, Hungary.




**Jay
      M. Green** ,
      age 58,
      has been the Executive Vice-President and a Director of the Company since
      September 2004. Mr. Green also currently serves as the Executive Vice President
      and Director of Inyx, Inc. Mr. Green has more than twenty years of business
      and
      financial experience, including serving as a corporate officer with New York
      Stock Exchange and American Stock Exchange-listed companies. From January until
      November 2003, Mr. Green was a managing director of Duncan Capital, LLC, a
      merchant banking/investment banking firm. From June 2001 until December 2002,
      Mr. Green was a Managing Director of BlueFire Partners, a Minneapolis-based
      capital markets advisory firm. From January 2001 until May 2001, Mr. Green
      served as an independent financial consultant advising both private and public
      companies. From June 2000 until December 2000, he was a Vice President with
      Unapix Entertainment, Inc., which was a public company on the American Stock
      Exchange (ASE: UPX) that filed for bankruptcy and its assets were subsequently
      liquidated. From March 1999 to May 2000, Mr. Green was an independent
      consultant advising private and public companies. From September 1998 until
      February 1999, he served as a Vice President with Paxar Corp. (NYSE: PXR).
      From
      January 1991 until May 1998, Mr. Green was a Vice President with Seitel,
      Inc. (which was on the AMEX and then the NYSE during his tenure).




13




**Director
      Compensation**




The
      Company does not currently compensate its directors.




**Audit**  **Committee**




We
      do not
      have a separate Audit Committee. Our full Board of Directors performs the
      functions usually designated to an Audit Committee. We do not currently have
      a
      financial expert serving on the Audit Committee because it is believed that
      the
      time and expense associated with locating such a financial expert is not
      justified during the time that the Company remains in the development stage
      and
      has relatively limited financial resources.




**Governance**




As
      we are
      not listed on a national stock exchange, we are not subject to the
      implementation of certain corporate governance requirements mandated by the
      Sarbanes-Oxley Act of 2002, as of the date of this filing.




**Code
      of Ethics**




We
      have
      not adopted a formal ethics policy for our chief executive officer or senior
      financial officers, due to our status as an Over-the-Counter Bulletin Board
      Company with only two management personnel. We believe that our Board can
      successfully oversee and manage our existing officers and employees. However,
      we
      believe that an ethics policy is important and intend to consider adopting
      such
      a policy in the future.




**Section
      16(a) Beneficial Ownership Reporting Compliance**




The
      Company does
      not
      file reports pursuant to Section 12 of the
      Securities Exchange Act of 1934, as amended, and its officers, directors, and
      10% shareholders are not required to file reports under Section 16(a) of
      the Securities Act.




**ITEM
      10.** **EXECUTIVE
      COMPENSATION**




The
      following table sets forth the compensation of the executives of the
      Company:




**Summary
      Compensation Table**


Name
                  and Principal Position
              
              Year
              
              Salary
              
              Bonus
              
              Stock
                  Awards
              
              Option
                  Awards
              
              Non-Equity
                  Incentive Plan Compensation
              
              Nonqualified
                  Deferred Compensation Earnings
              
              All
                  Other Compensation
              
              Total**Dr.
                  Jack Kachkar**
              
              
              2006
              
              $
              37,5000
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              $
              37,500Chief
                  ExecutiveOfficer
              
              
              2005
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              
              —**Jay
                  M. Green**
              
              
              2006
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              
              —Executive
                  Vice President
              
              
              2005
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              
              —
              
              
              —




The
      Company entered into an employment agreement with its Chief Executive Officer
      and President on October 1, 2006 for a five year term with an annual salary
      of
      $150,000, four weeks of vacation and a severance of twenty-four
      months.




As
      of
      December 31, 2006, there were no outstanding equity awards for the executives
      of
      the Company. The directors of the Company did not receive any cash or equity
      compensation during the year ended December 31, 2006.




14




**ITEM
              11.**
            **SECURITY
                OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT********AND
                RELATED STOCKHOLDER
                MATTERS**




The
      following table sets forth information regarding the beneficial ownership of
      our
      shares of common stock at March 26, 2007 by (i) each person known by us to
      be the beneficial owner of more than 5% of our outstanding shares of common
      stock, (ii) each of our directors, (iii) our executive officers, and
      (iv) all directors and executive officers as a group. Each person named in
      the
      table has sole voting and investment power with respect to all shares shown
      as
      beneficially owned by such person.




**Name
                and Address of Beneficial Owner**
            
            **Number
                of Shares Owned**
            
            **Percent
                of Class**First
                Jemini Trust
              Larry
                Stockhamer Trustee
              76
                Sanibel Crescent
              Thornhill,
                Ontario L4J 8K7
            
            
            5,086,600
            (1)
            
            37.29
            %Karver
                Holdings, Ltd.
              104
                West Shore Drive
              Putnam
                Valley, NY 10579
            
            
            2,336,659
            (2)
            
            17.13
            %Viktoria
                Benkovitch
              445
                Grand Bay Drive #1210
              Key
                Biscayne, FL 33149
            
            
            1,076,802
            (3)
            
            7.89
            %Jay
                M. Green
            
            
            -
            
            
            -Dr.
                Jack Kachkar
            
            
            -
            
            
            -All
                officers and directors as a group (2 persons)
            
            
            -
            
            
            -




(1)
            First
                Jemini Trust is a discretionary family trust for the benefit of our
                Chairman and Chief Executive Officer, his spouse, Ms. Viktoria Benkovitch
                and family members. Such beneficiaries possess no right to the Trust
                and
                therefore have no direct beneficial ownership of shares held by the
                Trustee.




(2)
            Karver
                Capital Holdings, Ltd., is a private investment holding company
                incorporated in the British Virgin Islands of which, Mr. Green, our
                Executive Vice President and Dr. Kachkar’s spouse, Ms. Viktoria
                Benkovitch, are co-owners. Subsequent to the year end Karver Capital
                Holdings, Ltd. changed its name to Karver Holdings,
                Ltd.




(3)
            Ms.
                Viktoria Benkovitch is the spouse of Dr. Kachkar, our Chairman and
                Chief Executive Officer. Dr. Kachkar disclaims beneficial ownership
                over
                the shares owned by Ms. Benkovitch.




**ITEM
              12.**
            **CERTAIN
                RELATIONSHIPS AND RELATED TRANSACTIONS****,
                AND DIRECTOR INDEPENDENCE**




Mr. Green
      and Dr. Kachkar’s spouse, Viktoria Benkovitch, are co-owners of Karver
      Holdings, Ltd. (“Karver Holdings”), formerly known as Karver Capital Holding,
      Ltd. (“Karver Capital”) a private investment holding company incorporated in the
      British Virgin Islands, which owns approximately 17% of the outstanding stock
      of
      the Company. Mr. Green is executive vice-president and a director of the
      Company. Ms. Benkovitch’s spouse, Dr. Jack Kachkar is the Chairman and director
      of the Company.




During
      the year ended December 31, 2006, the Company accrued management fees of
      $41,000, payable to an affiliated company for management services. Additionally,
      the Company accrued rent expense of approximately $26,000, also payable to
      the
      affiliated company for the rental of furnished office space under a sublease
      agreement, which was terminated August 31, 2006. These amounts are included
      in
      the general and administrative expenses of the Company’s consolidated statement
      of operations. At December 31, 2006, the total amount due to the affiliated
      company was approximately $6,000. The Company settles the outstanding amounts
      on
      a monthly basis.




15




During
      the year ended December 31, 2006, the Company entered into a short-term
      sub-lease agreement with the same affiliated company whereby commencing
      September 1, 2006, the Company agreed to sublease a portion of its office space
      in Miami, Florida, to the affiliate through March 31, 2007, for monthly rent
      income of $4,000. Prior to September 1, 2006, the Company had sub-leased this
      office space on a month to month basis for monthly rent income of $2,500. For
      the year ended December 31, 2006, the Company charged approximately $35,000
      for
      sublease rental income on this office space. Rent income is included in the
      consolidated statement of operations as an offset against rent
      expense.




Additionally,
      for the year ended December 31, 2006, the Company accrued professional fees
      relating to accounting and administrative support services provided by related
      parties (consultants related to the Company) amounting to approximately $70,000.
      These amounts are included as professional fees on the Company’s consolidated
      statement of operations. The total amount due to related parties was
      approximately $124,000 at December 31, 2006.




The
      Company’s Chairman and Chief Executive Officer provides funding on an ongoing
      basis for working capital requirements. At December 31, 2006, the total amount
      owing to the Chairman and Chief Executive Officer was approximately $765,000
      and
      is repayable on demand. The Company’s Chairman and Chief Executive Officer has
      agreed not to seek repayment of this loan for a minimum of 12 months from
      December 31, 2006. The Company accrues interest on such outstanding amount
      at 7%
      per annum and at December 31, 2006, such accrued interest was approximately
      $45,000.




**ITEM
      13.** **EXHIBITS**




**Exhibit
                Number**
            
            **Description
                of Exhibit**
            
            **Incorporated
                by Reference**2.1
            
            Asset
                Purchase Agreement dated September 13, 2004
            
            Filed
                as Exhibit 2.1 to Form 8-K filed on September 17, 20043.1.1
            
            Amended
                and Restated Certificate of Incorporation of Medeorex, Inc.
            
            Filed
                as Exhibit 3.1 to Form 8-K filed on September 29, 20043.1.2
            
            Amended
                and Restated Certification of Incorporation of Karver International,
                Inc.
            
            Filed
                as Exhibit 3.1 to Form 8-K filed on November 9, 20053.2
            
            Amended
                and Restated Bylaws of Medeorex, Inc.
            
            Filed
                as Exhibit 3.2 to Form SB-2 filed on September 28, 200010.1
            
            Share
                Exchange Agreement between Clixtix and Medeorex, dated September
                13,
                2004
            
            Filed
                as Exhibit 10.1 to Form 8-K filed on September 17, 200410.2
            
            Share
                Exchange Agreement between Phyllis Maxwell and First Jemini Trust
                dated
                September 13, 2004
            
            Filed
                as Exhibit 10.2 to Form 8-K filed on September 17, 200410.3
            
            Agreement
                and Mutual General Release dated April 15, 2005
            
            Filed
                as Exhibit 10.1 to Form 8-K filed on April 21, 200510.4
            
            Employment
                Agreement with Dr. Jack Kachkar, dated as of October 1,
                2006
            
            Filed
                herewith21
            
            Subsidiaries
                of the Registrant
            
            Filed
                herewith31.1
            
            Rule
                13a-14(a)/Rule 15d-14(a) Certification of Chief Executive Officer
                and
                Principal Financial Officer.
            
            Filed
                herewith32.1
            
            Certification
                pursuant to Section 1350 of Chapter 63 of Title 18 of the United
                States
                Code.
            
            Filed
                herewith





16




**ITEM
              14.**
            **PRINCIPAL
                ACCOUNTANT FEES AND
                SERVICES**




The
      Board
      of Directors has appointed Berkovits, Lago & Company, LLP as the
      Company’s independent auditors for 2006.




The
      following table lists the fees for services rendered by the independent
      registered public accounting firms for 2006 and 2005:





Audit
                Fees(1)
            
            Audit
                Related Fees
            
            Tax
                Fees
            
            All
                Other Fees2006
            
            $
            36,500
            
            $
            -
            
            $
            7,500
            
            $
            -2005
            
            $
            29,000
            
            $
            -
            
            $
            7,250
            
            $
            -





(1)
            Audit
                fees billed in 2006 and 2005 consisted of the audit of our annual
                financial statements, reviews of our quarterly financial statements,
                and
                statutory and regulatory audits, consents and other services related
                to
                filings with the SEC.




**SIGNATURES**





In
      accordance with Section 13 or 15(d) of the Exchange Act, the registrant has
      duly
      caused this report to be signed on its behalf by the undersigned, thereunto
      duly
      authorized.




KARVER
                INTERNATIONAL, INC.April
              2,
              2007
            By:
            /s/
              Dr.
              Jack KachkarDr.
                Jack KachkarChief
                Executive Officer, Principal FinancialOfficer,
                Secretary and Director





April
              2,
              2007
            By:
            /s/
              Jay
              M. GreenJay
                M. GreenExecutive
                Vice President and Director




17